1. Pink Sheet
  2. >>Geography
  3. >>Asia

Korea Can Play To Strengths But Also Improve Regulatory Flexibility For Clinical Trials

Rising Up Ranks Of Study Locations

 
• By Jung Won Shin

A session at the recent KoNECT conference in Seoul looked at Korea’s strengths in clinical trials but also at what's needed to further improve its global competitiveness as a location for studies.

2024 KoNECT international conference
Experts Discuss Korea’s Strengths, Challenges As Clinical Trial Sites (Jung Won Shin)

As global clinical trial activity continues to normalize from peak pandemic levels, the pharma industry is seeking to improve the efficiency of how such studies are conducted. As a result, competition between both countries and individual sites within these is intensifying.

Among the major Asian locations for trials, China already has the capacity and patient numbers to conduct large-scale Phase III programs - but also strict restrictions on the export of...

Key Takeaways
  • At the recent KoNECT international conference in Seoul, experts shared views that South Korea remains a "top tier" country for clinical trials, with diverse strengths...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from R&D

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.

UK MHRA’s Clinical Trial Lead On Combined Reviews, The Notification Scheme & Increasing Diversity

 
• By Eliza Slawther

In light of the UK’s MHRA announcing a major overhaul of its clinical trial legislation, the agency’s deputy director for clinical investigations and trials Andrea Manfrin tells the Pink Sheet what sponsors can expect from the new regulation.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.